- Home
- CNX vs DNTH Comparison
CNX vs DNTH Comparison
Compare CNX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNX | DNTH |
|---|---|---|
| Founded | 1860 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNX | DNTH |
|---|---|---|
| Price | $31.99 | $97.54 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $35.71 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $2,239,134,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.14 | $29.48 |
| P/E Ratio | $14.97 | ★ N/A |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.72 | $18.08 |
| 52 Week High | $43.62 | $102.33 |
Technical Indicators
Market Signals| Indicator | CNX | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 59.50 |
| Support Level | $31.69 | $79.27 |
| Resistance Level | $33.98 | $98.70 |
| Average True Range (ATR) | 0.81 | 5.37 |
| MACD | -0.02 | 0.87 |
| Stochastic Oscillator | 6.04 | 71.99 |
Price Performance
Historical ComparisonAbout CNX CNX Resources Corporation
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.